Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

LB Pharmaceuticals to Participate in Upcoming Investor Events

globenewswire.com
LBRX The article announces LB Pharmaceuticals' participation in upcoming investor events and conferences, which is standard corporate communication and does not inherently suggest a positive or negative outlook on the stock. It focuses on the company's pipeline and potential drug candidate.

LB Pharmaceuticals to Participate in Upcoming Investor Events NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences:

Craig-Hallum Biotech Catalyst Conference

Guggenheim Securities 3 rd Annual Healthcare Innovation Conference

Wolfe Research Healthcare Conference

Stifel Healthcare Conference

Webcasts for the fireside chats will be available on the “Investors” section under the “ Events” page of the Company’s website at https://ir.lbpharma.us/, where a replay of the webcasts will be archived.

About LB Pharmaceuticals

LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.

Media and Investor Contact:

Ellen Rose

erose@lbpharma.us